Physician profile
Nirav R Amin
NPI 1609187897
$7,263.37
in general payments reported to CMS, 2019-2025
15 companies · $960 in 2025
The $960 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $300 · 2021: $764 · 2022: $386 · 2023: $51.04 · 2024: $4,000 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,564 · Food and Beverage: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,564.32 |
| Food and Beverage | $447.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $3,240.57 | 2024-2025 | Samples Biologics, Comprehensive Shoulder System |
| Smith+Nephew, INC. | $1,615.34 | 2024-2025 | Real Intelligence |
| Janssen Pharmaceuticals, INC | $742.18 | 2019-2022 | |
| Pfizer INC. | $592.01 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $325.78 | 2019-2023 | |
| Abbott Laboratories | $242.46 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $143.39 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $103.00 | 2020-2024 | Eliquis |
| Abbvie INC. | $78.27 | 2021-2025 | Dalvance |
| Boston Scientific Corporation | $55.39 | 2021-2024 | Spyglass Discover |
| Astrazeneca Pharmaceuticals Lp | $33.25 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $31.60 | 2019 | |
| Genzyme Corporation | $20.85 | 2020 | |
| Melinta Therapeutics, LLC | $20.56 | 2022 | |
| Vifor Pharma, INC. | $18.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.